Bookmark

Add to MyYahoo RSS

Gilead Sciences News

News on Gilead Sciences (Ticker: GILD) continually updated from thousands of sources around the net.

19 hrs ago | WTOP-FM Washington

$1,000 Sovaldi now hepatitis treatment of choice

The price is sky-high, but so is demand. A new $1,000-per-pill drug has become the treatment of choice for Americans with hepatitis C, a liver-wasting disease that affects more than 3 million.

Comment?

Related Topix: Hepatitis, Medicine, Health, Biotech, Gilead Sciences, Healthcare Industry, Startups, Health Insurance, Medicaid

Thu Jul 31, 2014

Kidney International

Contribution of the organic anion transporter OAT2 to the renal...

Correspondence: Adrian S. Ray, Gilead Sciences, 333 Lakeside Drive, Foster City, California 94404, USA.

Comment?

Related Topix: Biotech, Startups, Medicine, Gilead Sciences, CGI Pharmaceuticals, Healthcare Industry, San Mateo County, CA, Foster City, CA

Seeking Alpha

3 Biotech Catalyst Stocks To Own

For companies involved in the research of drugs, no catalyst is able to trump coming out with clinical trial results.

Comment?

Related Topix: Healthcare Law, Law, Biotech, Medicine, Gilead Sciences, Healthcare Industry, Startups, HIV/AIDS, Health, Viread, Tenofovir (generic), Xoma

Daily Chronicle

Illinois Medicaid restricts use of hepatitis drug

This handout photo provided by Gilead Sciences shows the hepatitis C medication Sovaldi.

Comment?

Related Topix: Medicaid, Health, Illinois, Illinois Government, Hepatitis, Medicine, Biotech, Gilead Sciences, Healthcare Industry, Startups, Northwestern University

Wed Jul 30, 2014

Seeking Alpha

Gilead's Massive Undervaluation: A Pictorial Overview

Despite the rally in the stock the shares are still extremely cheap compared to other large cap biotech concerns as well as against other large cap growth plays.

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry, Startups, CGI Pharmaceuticals, Celgene, Regeneron Pharmaceuticals

BioSpace

Gilead Sciences, Inc. Allows China/Indian Pharmas To Make Generic Version Of Novel HIV Drug

July 29, 2014 -- Gilead Sciences will allow China and Indian drugmakers to start developing generic formulations of a promising novel HIV/HBV drug, even though the drug's Phase III tests are still underway.

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry, HIV/AIDS, Health, Startups, Viread, Tenofovir (generic)

Forbes.com

Gilead Sciences Popular Amongst Latest 13F Filers

At Holdings Channel , we have reviewed the latest batch of the 23 most recent 13-F filings for the 06/30/2014 reporting period, and noticed that Gilead Sciences, Inc. was held by 13 of these funds.

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry, Startups, CGI Pharmaceuticals, Financial Markets

Business Journal

Theraclone Sciences cuts HIV antibodies deal with Gilead

Theraclone Sciences Inc. of Seattle said it's made a deal with Gilead Sciences Inc. that will allow the Foster City-based biotech giant to develop and commercialize Theraclone's neutralizing HIV-antibodies for therapeutic applications in HIV.

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry, Theraclone Sciences, Startups

Tue Jul 29, 2014

Ledger-Enquirer.com

$1,000 pill now hepatitis C treatment of choice

In less than six months, prescriptions for Sovaldi have eclipsed all other hepatitis C pills combined, according to new data from IMS Health.

Comment?

Related Topix: Hepatitis, Medicine, Health, Biotech, Gilead Sciences, Healthcare Industry, Startups, Health Insurance, Medicaid

Mon Jul 28, 2014

SFGate

In Europe, two drugs will compete to treat rare blood cancer

In Europe, two Bay Area pharmaceutical companies will go head-to-head over new drugs that both treat a rare blood cancer, chronic lymphocytic leukemia, in patients whose disease has returned.

Comment?

Related Topix: Medicine, Cancer, Health, Leukemia, Biotech, Startups, Gilead Sciences, CGI Pharmaceuticals, Healthcare Industry, Pharmacyclics

Freshnews

Diplomat receives distribution contract for ZydeligA

Diplomat, the nation's largest independent specialty pharmacy, announced today that it has been selected as a provider of Zydelig tablets.

Comment?

Related Topix: Food and Drug Administration, Biotech, Gilead Sciences, Healthcare Industry, Leukemia, Health, Startups

TheStreet.com

Why Gilead Sciences (GILD) Stock Is Up Today

Your browser is not supported. Please upgrade to one of the following browsers: Google Chrome Mozilla Firefox Apple Safari Microsoft Internet Explorer 8+ You may proceed to the site by clicking here , however some pages might not work correctly.

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry, Startups, Mozilla, Science / Technology, TheStreet, Financial Markets

TheStreet.com

Why Gilead Sciences (GILD) Stock Is Up Today

The company's new price target represents 41% upside from its opening price today.

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry, Startups, Science / Technology, Financial Markets

Sat Jul 26, 2014

The Motley Fool

This Week in Biotech: Puma Sprints, Gilead Sweeps, and Inovio Hits the Mark

With the SPDR S&P Biotech Index up 22% over the trailing 12-month period , it's evident that investment dollars are willingly flowing into the biotech sector.

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry, Science / Technology, Startups, CGI Pharmaceuticals, Healthcare Law, Food and Drug Administration, Law

Fri Jul 25, 2014

JD Supra

Gilead Sciences, Inc. v. Natco Pharma Ltd.

Case Name: Gilead Sciences, Inc. v. Natco Pharma Ltd. , 2013-1418, 2014 U.S. App.

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry, Startups, Tamiflu, Oseltamivir (generic), Inventions, Science / Technology

Q-Notes

Science and Society: Let's Fight HIV and Hep C Together

Scientists and community members have striven to make their points and find common ground on this last full day of the XX International AIDS Conference on Thursday.

Comment?

Related Topix: HIV/AIDS, Health, Hepatitis, Medicine, Biotech, Gilead Sciences, Healthcare Industry, Startups, Food and Drug Administration, Prison

Investor's Business Daily

European CHMP Adopts Positive Opinion for Gilead's Zydelig ...

Gilead Sciences, Inc. today announced that the Committee for Medicinal Products for Human Use , the scientific committee of the European Medicines Agency , has adopted a positive opinion on the company's Marketing Authorization Application for ZydeligA , a first-in-class treatment for patients with chronic lymphocytic leukemia and follicular ... (more)

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry, Startups, Marketing, Leukemia, Health, Lymphoma, Opinion

Medical News

$1,000-a-pill hepatitis C drug boosts Gilead's fortunes

Sales of the new hepatitis C drug Sovaldi reached $3.5 billion in the second quarter, putting it on track to become one of the world's best-selling medicines and intensifying concerns about its costs.

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry, Hepatitis, Health, Medicare, Startups

Thu Jul 24, 2014

SFGate

Gilead hepatitis C pill reaches $3.48 billion in quarterly sales

Despite criticism from insurers and lawmakers, Gilead Sciences said Wednesday its $1,000-a-day hepatitis C pill had improved on its record-setting debut as it reached $3.48 billion in sales last quarter.

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry, Hepatitis, Health, Startups, CGI Pharmaceuticals, Cancer, Business News

Medical Daily

Sovaldi Debate Continues: Will Medicaid And Insurance Companies...

Since gaining approval from the Food and Drug Administration in December, Sovaldi, the hepatitis C drug, has courted controversy due to its steep $1,000-a-pill price.

Comment?

Related Topix: Hepatitis, Medicine, Medicaid, Food and Drug Administration, Biotech, Gilead Sciences, Healthcare Industry, Startups

•••
•••
•••
•••
•••

Ashburn Jobs

•••
•••
•••
•••